Discover & Define

Challenge: A Fragmented, Overwhelming Market

• Despite growing interest in longevity and preventative healthcare, consumers struggle with navigating multiple providers, lack of transparency in treatment options, and affordability concerns.

Solution: A Seamless, Science-Backed Platform

BIOVERSE is the first AI-powered, digitally native, fully vertically anti-aging & longevity platform, providing access to high-quality, preventative care – from first consultation to ongoing treatment.

Key Demographics: Who actually wants to live forever?

We identified two core audiences – but with distinct needs.

• Men (35-55) saw longevity as an extension of performance. They weren’t just aging; they were optimizing. Testosterone support, cognitive function, and metabolic health were at the top of their list.

• Women (25-45) approached aging differently. For them, longevity wasn’t just about extending life but improving quality of life – hormonal balance, reproductive health, and proactive aging solutions mattered most. Surprisingly, research showed women start anti-aging treatments as early as 26 on average.

Project Goals

1. Identify consumer expectations and motivations in pursuing longevity treatments, including desired product attributes and the ideal user experience for a science-backed, tech-enabled service.

2. Determine differentiating opportunities in a fragmented ecosystem, particularly at the intersection of AI diagnostics, personalized medicine, and telehealth.

Process

Before my arrival, the founder defined our initial product offerings: pharmaceuticals, nutraceuticals, AI at-home testing, and personalized consultations. Using these categories, we collaborated with board-certified medical experts to develop initial intake questionnaires and treatment frameworks for each product. Investing in the product offering, first and foremost, laid a strong foundation for further iterations and growth.

To understand where longevity care was failing, we studied direct-to-consumer telehealth companies like Hims, Hers, Ro, AgelessRx, and Eden Health. Some had strong user experiences but lacked credibility, while others felt medically sound but outdated. Surveys and market research confirmed that users were overwhelmed by the sheer number of choices and skeptical about AI making medical decisions. To validate our findings, we worked closely with board-certified longevity specialists to ensure that BIOVERSE’s intake flows, treatment plans, and compliance measures met both user expectations and industry standards.

One of our biggest insights was that while users were open to AI-assisted recommendations, they still wanted a doctor involved in the final decision-making process. This shaped BIOVERSE’s core product philosophy—AI would not replace medical expertise but enhance it. Users also wanted clear, science-backed education embedded in the experience rather than vague marketing claims. This led to a shift in our onboarding strategy, where we incorporated progressive education to guide users through their treatment options with clarity and transparency.

We also found that consumers wanted more control over their treatment selection, rather than being required to complete a full intake before exploring options. This insight led us to restructure the product experience, allowing users to browse available treatments upfront, increasing engagement and trust. Additionally, real-time provider chat emerged as a key trust-builder, reinforcing the importance of doctor-led care. Another unexpected finding was the demand for proof, not just promises. Users wanted to see tangible improvements in their health, which led us to prioritize biomarker tracking, allowing patients to monitor their biological age over time.

With these insights, we refined BIOVERSE’s positioning as a highly personalized, science-backed longevity platform—one that met users where they were, balanced innovation with trust, and made longevity care not just aspirational, but accessible.

Ideate & Execute: From Concept to Conversion

To build a sustainable foundation, we defined our MVP as a D2C telemedicine platform focused solely on personalized pharmaceutical longevity treatments. Instead of launching with a broad range of offerings, we streamlined access to science-backed prescriptions that provided immediate, tangible benefits for users. This approach validated our business model, gained early market traction, and optimized the tech-enabled patient experience before expanding into AI diagnostics and nutraceuticals.

MVP Components

• Telemedicine-First Model: BIOVERSE launched with a telehealth-driven infrastructure, integrating HIPAA-compliant virtual consultations with board-certified providers. Focused on fast, frictionless access to longevity-focused prescriptions without requiring in-person visits.

• Secure, Mobile-Optimized Platform: Ensured a seamless mobile-first experience with real-time messaging between patients and providers. We also provide education about prescription’s purposes, efficacy, and quality to establish credibility and trust with our users.

• Personalized Longevity Prescriptions: Initial product offering focused on science-backed pharmaceuticals with clear, transparent education on treatment benefits. Established a subscription-based model to drive higher retention & LTV while keeping CAC sustainable.

BIOVERSE needed high conversion rates to sustain its subscription-driven model while ensuring a trust-driven, user-friendly medical experience. To meet both objectives, we focused on three key priorities: reducing friction in onboarding, reinforcing credibility at every step, and making treatments feel accessible rather than experimental.

Initially, we explored different onboarding approaches. A single-step intake form seemed like the fastest way to get users through the funnel but led to high drop-off rates due to decision fatigue. Through A/B testing and user behavior analysis, we landed on a multi-step adaptive intake flow. By placing lighter, confidence-boosting questions first (such as lifestyle goals) and delaying medical history until later, we increased intake completion rates by 30%.

Design Principles & Frameworks

The platform’s UX was built on three core design pillars: trust, accessibility, and conversion. Given the mobile-first nature of telehealth, the design followed WCAG accessibility standards, ensuring readability, high contrast, and large touch targets. For credibility, we leaned into science-backed UI patterns, structuring the interface to mirror leading medical platforms while embedding progressive education on prescriptions and longevity science. Intake flows were guided by Hick’s Law, keeping decision-making steps minimal and intuitive to reduce cognitive overload. To improve conversion, we leveraged Jakob’s Law, using familiar UI components from successful telehealth products, ensuring the experience felt seamless to new users.

Leveraging AI for Personalization & Efficiency

AI played a supporting role, not a lead actor in BIOVERSE’s patient journey. Instead of making direct treatment decisions, AI was used to automate provider workflows, and enhance personalization. This ensured that all final decisions remained in the hands of board-certified medical providers. This hybrid approach increased patient trust while reducing clinician workload, making care delivery more efficient.

Collaboration with Engineers & Medical Teams

BIOVERSE was a cross-functional effort, requiring tight coordination across design, engineering, operations, and medical teams. From the outset, I worked closely with engineers to assess the development lift of each design feature, ensuring that every component was scalable, feasible, and aligned with sprint cycles. Having led engineering teams in past roles, I prioritized detailed design documentation to minimize development bottlenecks. I also partnered with medical experts to ensure that intake questions and treatment descriptions met compliance regulations while maintaining an approachable user experience.

Optimizing Patient Intake for Conversion: Biggest Design Challenge

The most complex design challenge was balancing conversion with a seamless medical intake process. Users needed to move through onboarding quickly without feeling like they were rushing through a critical medical decision. To address this, we structured intake flows with progressive disclosure, guiding users step by step while removing unnecessary cognitive friction. A/B tests showed that breaking the form into digestible steps reduced drop-offs significantly, leading to an increase in overall treatment adoption.

Testing & Refinement

If it can’t be measured, it can’t be improved. Design decisions were backed by data-driven iteration cycles. We combined A/B testing with heatmap tracking to monitor user behavior, refining forms for clarity and engagement. Weekly design reviews and cross-functional standups ensured fast iteration loops, allowing us to fine-tune the onboarding experience in real-time.

Next Steps

Post-launch, user response was overwhelmingly positive, particularly regarding seamless onboarding, intuitive workflows, and AI-powered provider support. Patients completed intake forms at rates exceeding industry benchmarks, validating our approach to personalization and transparency. Clinicians reported that the AI-driven workflows streamlined operations and reduced administrative friction.

Building on our successful pharmaceutical model, BIOVERSE's next phase will expand AI-powered diagnostics and introduce nutraceutical offerings. Users have shown strong interest in tracking improvements in biological age and health markers, creating opportunities for gamification and long-term engagement features. Through patient data insights, we'll develop predictive health algorithms to recommend treatments proactively, transforming BIOVERSE from reactive care to preventative, AI-driven longevity management.

Our early behavioral data highlighted key areas for improvement. Users desired more control over treatment selection before consultation, prompting us to introduce flexible browsing before intake.

Technically, scalability and compliance are our key considerations. Expanding AI diagnostics requires secure integrations with biometric data sources and advanced testing labs, while maintaining HIPAA compliance and data security. Our development team will focus on enhancing the AI decision-making framework, optimizing performance for higher patient volumes, and expanding cross-platform compatibility to ensure seamless experiences across devices.

BIOVERSE's long-term vision remains clear: transform longevity care from reactive to predictive, using AI to empower users with data-driven, personalized health insights that evolve with them.

Conclusion

Key Takeaways

• Designing for trust is just as important as designing for conversion. Patients need transparency, credibility, and reassurance at each step to feel confident in their decisions.

• AI should enhance, not replace, human expertise. While automation improved efficiency, users responded best when we introduced AI as a support tool rather than the primary decision-maker.

• Designing for longevity is designing for long-term engagement. Beyond optimizing onboarding, the real challenge was creating a system that kept users engaged and invested in their health over time.

BIOVERSE, in essence, means proving that longevity care could be both accessible and trustworthy. Intake completion rates exceeding industry benchmarks showed we had removed friction, while high retention validated that patients saw long-term value in their treatments.

This project pushed me as designer, strategist, and cross-functional leader, balancing UX, AI, medical compliance, and business objectives. BIOVERSE reflects my approach to creating thoughtful, user-centered solutions that not only meet immediate goals but are also built for long-term growth and engagement.